General
Preferred name
DIMERCAPROL
Synonyms
Dicaptol ()
Dithiopropanol ()
2,3-Dimercapto-1-propanol ()
Dithioglycerol ()
Bal, 2,3-Dimercapto-1-propanol, Dithioglycerol ()
2,3-dithiopropan-1-ol ()
NSC-39515 ()
Sulfactin ()
Antoxol ()
2,3-dithiopropanol ()
NSC-4646 ()
B.A.L. ()
1-propanol, 2,3-dimercapto ()
BAL ()
Dimersol ()
Panobal ()
Anti-Lewisite ()
2,3,-dimercapto-1-propanol ()
Dimercaprolum ()
P&D ID
PD002368
CAS
59-52-9
31855-41-1
Tags
natural product
drug
available
Approved by
FDA
First approval
1946
Drug Status
approved
Max Phase
Phase 4
Drug indication
Antidote (to arsenic and gold and mercury poisoning)
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Due to its oily nature, dimercaprol is not absorbed orally and its administration requires a deep intra-muscular injection that is extremely painful and allergenic. It was found to mobilize and relocate lead to the brain, increasing its neurotoxic effects. Despite that fact that dimercaprol increases cadmium excretion, there is an associated increase in kidney cadmium concentration. Because of this, dimercaprol must be avoided in patients with cadmium toxicity.
Compound Sets
12
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
124.0
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
0.21
TPSA
20.23
Fraction CSP3
1.0
Chiral centers
1.0
Largest ring
0.0
QED
0.45
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Cadmium
Mercury
HIV
Pathway
Anti-infection
Source data